How To Use RWE To Optimize P&R Of New Health Technologies

October 4, 2018 Danielle Twigg

Utilizing real world evidence (RWE) of disease burden and performance of technologies in clinical practice settings is increasingly a focus of the healthcare industry. However, the willingness and ability to use RWE in reimbursement decision-making varies significantly. This research aims to classify major national payers into archetypes based on their use of RWE in decision-making.

Authors: Macaulay R, Tang M, PAREXEL International, London, United Kingdom

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?
NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?

Next Article
Real World Evidence: Does The Popularity Of The Term Reflect In Publication Numbers?
Real World Evidence: Does The Popularity Of The Term Reflect In Publication Numbers?